ChunPeng personal page - To The Moon

ChunPeng

ChunPeng

No personal profile

35Follow

5Followers

0Topic

0Badge

2021-01-28

$Obseva Sa(OBSV)$Be patient ?

2021-09-16

$Tiger Brokers(TIGR)$Everyday goes down

2021-09-16

$Surface Oncology(SURF)$Cut losses and move on. Not worried anymore.

2021-04-02

Nice

Sorry, the original content has been removed

2021-02-14

?

Vivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end

2021-01-16

Great ariticle, would you like to share it?

@英伟达官方:新年新動力：NVIDIA DRIVE賦能領先電動汽車製造商開啓2021

2022-08-12

$Tesla Motors(TSLA)$Hold

2021-08-13

$VYNE Therapeutics Inc.(VYNE)$What happen to this company?

2021-02-14

Sanofi failed his 3rd stages...

Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO

2021-02-06

Not too good

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3553468686052330","uuid":"3553468686052330","gmtCreate":1590374663493,"gmtModify":1612234242754,"name":"ChunPeng","pinyin":"chunpeng","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":35,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9907708803,"gmtCreate":1660255727604,"gmtModify":1676531200111,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>Hold","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>Hold","text":"$Tesla Motors(TSLA)$Hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907708803","isVote":1,"tweetType":1,"viewCount":2382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885276880,"gmtCreate":1631800609540,"gmtModify":1676530639483,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Everyday goes down&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Everyday goes down&nbsp;","text":"$Tiger Brokers(TIGR)$Everyday goes down","images":[{"img":"https://static.tigerbbs.com/13b660a5446aa4be321d11fa689957a8","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885276880","isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885978034,"gmtCreate":1631753960928,"gmtModify":1676530625545,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Cut losses and move on.&nbsp;Not worried&nbsp;anymore.","listText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Cut losses and move on.&nbsp;Not worried&nbsp;anymore.","text":"$Surface Oncology(SURF)$Cut losses and move on. Not worried anymore.","images":[{"img":"https://static.tigerbbs.com/e2d7af4f061899ec6557834e13245ff5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/885978034","isVote":1,"tweetType":1,"viewCount":3632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885979248,"gmtCreate":1631753804784,"gmtModify":1676530625490,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>Finally I decid dto&nbsp;give up&nbsp;VYNE.&nbsp;","listText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>Finally I decid dto&nbsp;give up&nbsp;VYNE.&nbsp;","text":"$VYNE Therapeutics Inc.(VYNE)$Finally I decid dto give up VYNE.","images":[{"img":"https://static.tigerbbs.com/8fc215c384330dfbc19b446070356be5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885979248","isVote":1,"tweetType":1,"viewCount":2966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":894786263,"gmtCreate":1628857491852,"gmtModify":1676529876357,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?&nbsp;","listText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?&nbsp;","text":"$VYNE Therapeutics Inc.(VYNE)$What happen to this company?","images":[{"img":"https://static.tigerbbs.com/a7c206b6845d177c23ae34177ed6d7a5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894786263","isVote":1,"tweetType":1,"viewCount":2301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":116703862,"gmtCreate":1622817549156,"gmtModify":1704191852906,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?","listText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?","text":"$VYNE Therapeutics Inc.(VYNE)$What happen to this company?","images":[{"img":"https://static.tigerbbs.com/c5ef85bbab8d041dabda3826393ab5da","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/116703862","isVote":1,"tweetType":1,"viewCount":2703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":104498878,"gmtCreate":1620401462094,"gmtModify":1704343260079,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>When will this stock can go up again?","listText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>When will this stock can go up again?","text":"$VYNE Therapeutics Inc.(VYNE)$When will this stock can go up again?","images":[{"img":"https://static.tigerbbs.com/9f45ebe32278206b1409cf4db45055ad","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/104498878","isVote":1,"tweetType":1,"viewCount":2495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":347867166,"gmtCreate":1618486266755,"gmtModify":1704711559393,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347867166","repostId":"345255525","repostType":1,"repost":{"id":345255525,"gmtCreate":1618321130667,"gmtModify":1704709098486,"author":{"id":"3574041672989370","authorId":"3574041672989370","name":"克罗伊","avatar":"https://static.tigerbbs.com/43f42ce5b407f9b6b1fffd313280897b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574041672989370","idStr":"3574041672989370"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>Sell or hold?","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>Sell or hold?","text":"$Senseonics(SENS)$Sell or hold?","images":[{"img":"https://static.tigerbbs.com/9cc56fda0d2e9cc3f457a88bab42af3a","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/345255525","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340124773,"gmtCreate":1617360530392,"gmtModify":1704699169785,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340124773","repostId":"1112964874","repostType":4,"isVote":1,"tweetType":1,"viewCount":3757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":360081157,"gmtCreate":1613795587279,"gmtModify":1704885139074,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Sign of market recover","listText":"Sign of market recover","text":"Sign of market recover","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/360081157","repostId":"2112844585","repostType":2,"isVote":1,"tweetType":1,"viewCount":2775,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385497016,"gmtCreate":1613570893235,"gmtModify":1704882183755,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Very good along with the rise of bitcoin?","listText":"Very good along with the rise of bitcoin?","text":"Very good along with the rise of bitcoin?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/385497016","repostId":"2112983095","repostType":2,"repost":{"id":"2112983095","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613568120,"share":"https://ttm.financial/m/news/2112983095?lang=en_US&edition=fundamental","pubTime":"2021-02-17 21:22","market":"hk","language":"en","title":"Square stock price target raised to $330 from $255 at Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2112983095","media":"Dow Jones","summary":"MW Square stock price target raised to $330 from $255 at Deutsche Bank\n\n\n \n\n\n$(END)$ Dow Jones Newsw","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Square stock price target raised to $330 from $255 at Deutsche Bank\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  February 17, 2021 08:22 ET (13:22 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Square stock price target raised to $330 from $255 at Deutsche Bank</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSquare stock price target raised to $330 from $255 at Deutsche Bank\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-17 21:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Square stock price target raised to $330 from $255 at Deutsche Bank\n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  February 17, 2021 08:22 ET (13:22 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DB":"德意志银行"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112983095","content_text":"MW Square stock price target raised to $330 from $255 at Deutsche Bank\n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  February 17, 2021 08:22 ET (13:22 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"DB":1,"SQ":0.9}},"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386797164,"gmtCreate":1613271151458,"gmtModify":1704879660334,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/386797164","repostId":"2111722630","repostType":2,"repost":{"id":"2111722630","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613214929,"share":"https://ttm.financial/m/news/2111722630?lang=en_US&edition=fundamental","pubTime":"2021-02-13 19:15","market":"us","language":"en","title":"Vivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end","url":"https://stock-news.laohu8.com/highlight/detail?id=2111722630","media":"Reuters","summary":"By Dominique Vidalon   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribut","content":"<html><body><p>By Dominique Vidalon</p><p>   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year. </p><p>   The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.  </p><p>   \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group <a href=\"https://laohu8.com/S/UMG.AU\">$(UMG.AU)$</a> to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.</p><p>   The French conglomerate said the distribution would take the form of a special dividend.</p><p>    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.</p><p>   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.  </p><p>   Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.</p><p>   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    </p><p>($1 = 0.8252 euros)</p><p> (Reporting by Dominique Vidalon. Editing by Jane Merriman)</p><p>((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-13 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Dominique Vidalon</p><p>   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year. </p><p>   The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.  </p><p>   \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group <a href=\"https://laohu8.com/S/UMG.AU\">$(UMG.AU)$</a> to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.</p><p>   The French conglomerate said the distribution would take the form of a special dividend.</p><p>    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.</p><p>   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.  </p><p>   Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.</p><p>   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    </p><p>($1 = 0.8252 euros)</p><p> (Reporting by Dominique Vidalon. Editing by Jane Merriman)</p><p>((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","TCEHY":"腾讯控股ADR","00700":"腾讯控股","TME":"腾讯音乐"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111722630","content_text":"By Dominique Vidalon   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year.    The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.     \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group $(UMG.AU)$ to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.   The French conglomerate said the distribution would take the form of a special dividend.    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.     Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    ($1 = 0.8252 euros) (Reporting by Dominique Vidalon. Editing by Jane Merriman)((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))","news_type":1,"symbols_score_info":{"QNETCN":0.6,"00700":0.9,"TME":0.9,"TCEHY":0.6}},"isVote":1,"tweetType":1,"viewCount":1040,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386794771,"gmtCreate":1613271099293,"gmtModify":1704879660009,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Sanofi failed his 3rd stages...","listText":"Sanofi failed his 3rd stages...","text":"Sanofi failed his 3rd stages...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386794771","repostId":"2111807728","repostType":2,"repost":{"id":"2111807728","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613256424,"share":"https://ttm.financial/m/news/2111807728?lang=en_US&edition=fundamental","pubTime":"2021-02-14 06:47","market":"us","language":"en","title":"Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2111807728","media":"Reuters","summary":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Transla","content":"<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-14 06:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","TBIO":"Telesis Bio, Inc.","PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111807728","content_text":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Translate Bio  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.   In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.     \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.   The CEO gave no other details. Officials at Sanofi were not available for comment.   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.     To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.     Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly. (Reporting by Matthias Blamont; Editing by Dominique Vidalon)((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))","news_type":1,"symbols_score_info":{"PFE":0.9,"TBIO":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386085542,"gmtCreate":1613112716486,"gmtModify":1704878517526,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Good?","listText":"Good?","text":"Good?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386085542","repostId":"2110402716","repostType":2,"isVote":1,"tweetType":1,"viewCount":1057,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388631036,"gmtCreate":1613053262725,"gmtModify":1704877834670,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"RIOT is&nbsp;blasting off&nbsp;","listText":"RIOT is&nbsp;blasting off&nbsp;","text":"RIOT is blasting off","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/388631036","repostId":"2110602366","repostType":2,"repost":{"id":"2110602366","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613051742,"share":"https://ttm.financial/m/news/2110602366?lang=en_US&edition=fundamental","pubTime":"2021-02-11 21:55","market":"us","language":"en","title":"BRIEF-Riot Blockchain Says Will Achieve Estimated Hash Rate Capacity Of 1.06 Exahash Per Second With Deployment Of 2,002 S19 Pro Antminers","url":"https://stock-news.laohu8.com/highlight/detail?id=2110602366","media":"Reuters","summary":"Feb 11 (Reuters) - Riot Blockchain Inc   :   * RIOT BLOCKCHAIN- ANNOUNCED THAT WILL ACHIEVE ESTIMATE","content":"<html><body><p>Feb 11 (Reuters) - Riot Blockchain Inc   :</p><p>   * RIOT BLOCKCHAIN- ANNOUNCED THAT WILL ACHIEVE ESTIMATED HASH RATE CAPACITY OF 1.06 EXAHASH PER SECOND WITH DEPLOYMENT OF 2,002 S19 PRO ANTMINERS</p><p>   * RIOT BLOCKCHAIN INC - CONTINUES TO RECEIVE AND DEPLOY NEXT-GENERATION MINERS FROM BITMAIN</p><p>   * RIOT BLOCKCHAIN INC - REMAINS ON SCHEDULE TO MORE THAN TRIPLE CURRENTLY DEPLOYED CAPACITY BY Q4 OF 2021</p><p>   * RIOT BLOCKCHAIN - HAS AN ADDITIONAL 26,100 S19 PRO AND S19J ANTMINERS ON ORDER WITH BITMAIN, SCHEDULED FOR SHIPMENT EACH MONTH THROUGH OCTOBER 2021</p><p>   * RIOT BLOCKCHAIN -ONCE DEPLOYED, ESTIMATES WILL HAVE 37,642 BITMAIN ANTMINERS IN OPERATION WITH ESTIMATED BITCOIN MINING HASH RATE CAPACITY OF 3.8 EH/S</p><p>   * RIOT BLOCKCHAIN - BASED ON RECENT SHIPMENTS, ANTICIPATES CONTINUED TIMELY SHIPMENTS IN ACCORDANCE WITH BITMAIN PURCHASE ORDERS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Riot Blockchain Says Will Achieve Estimated Hash Rate Capacity Of 1.06 Exahash Per Second With Deployment Of 2,002 S19 Pro Antminers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Riot Blockchain Says Will Achieve Estimated Hash Rate Capacity Of 1.06 Exahash Per Second With Deployment Of 2,002 S19 Pro Antminers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-11 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 11 (Reuters) - Riot Blockchain Inc   :</p><p>   * RIOT BLOCKCHAIN- ANNOUNCED THAT WILL ACHIEVE ESTIMATED HASH RATE CAPACITY OF 1.06 EXAHASH PER SECOND WITH DEPLOYMENT OF 2,002 S19 PRO ANTMINERS</p><p>   * RIOT BLOCKCHAIN INC - CONTINUES TO RECEIVE AND DEPLOY NEXT-GENERATION MINERS FROM BITMAIN</p><p>   * RIOT BLOCKCHAIN INC - REMAINS ON SCHEDULE TO MORE THAN TRIPLE CURRENTLY DEPLOYED CAPACITY BY Q4 OF 2021</p><p>   * RIOT BLOCKCHAIN - HAS AN ADDITIONAL 26,100 S19 PRO AND S19J ANTMINERS ON ORDER WITH BITMAIN, SCHEDULED FOR SHIPMENT EACH MONTH THROUGH OCTOBER 2021</p><p>   * RIOT BLOCKCHAIN -ONCE DEPLOYED, ESTIMATES WILL HAVE 37,642 BITMAIN ANTMINERS IN OPERATION WITH ESTIMATED BITCOIN MINING HASH RATE CAPACITY OF 3.8 EH/S</p><p>   * RIOT BLOCKCHAIN - BASED ON RECENT SHIPMENTS, ANTICIPATES CONTINUED TIMELY SHIPMENTS IN ACCORDANCE WITH BITMAIN PURCHASE ORDERS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2110602366","content_text":"Feb 11 (Reuters) - Riot Blockchain Inc   :   * RIOT BLOCKCHAIN- ANNOUNCED THAT WILL ACHIEVE ESTIMATED HASH RATE CAPACITY OF 1.06 EXAHASH PER SECOND WITH DEPLOYMENT OF 2,002 S19 PRO ANTMINERS   * RIOT BLOCKCHAIN INC - CONTINUES TO RECEIVE AND DEPLOY NEXT-GENERATION MINERS FROM BITMAIN   * RIOT BLOCKCHAIN INC - REMAINS ON SCHEDULE TO MORE THAN TRIPLE CURRENTLY DEPLOYED CAPACITY BY Q4 OF 2021   * RIOT BLOCKCHAIN - HAS AN ADDITIONAL 26,100 S19 PRO AND S19J ANTMINERS ON ORDER WITH BITMAIN, SCHEDULED FOR SHIPMENT EACH MONTH THROUGH OCTOBER 2021   * RIOT BLOCKCHAIN -ONCE DEPLOYED, ESTIMATES WILL HAVE 37,642 BITMAIN ANTMINERS IN OPERATION WITH ESTIMATED BITCOIN MINING HASH RATE CAPACITY OF 3.8 EH/S   * RIOT BLOCKCHAIN - BASED ON RECENT SHIPMENTS, ANTICIPATES CONTINUED TIMELY SHIPMENTS IN ACCORDANCE WITH BITMAIN PURCHASE ORDERSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"RIOT":0.9}},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":381691089,"gmtCreate":1612959553041,"gmtModify":1704876530352,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Hope Elon will think alternative than Bitcoin like Ethereum?","listText":"Hope Elon will think alternative than Bitcoin like Ethereum?","text":"Hope Elon will think alternative than Bitcoin like Ethereum?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/381691089","repostId":"2110695015","repostType":2,"isVote":1,"tweetType":1,"viewCount":1337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383687274,"gmtCreate":1612874011598,"gmtModify":1704875236568,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383687274","repostId":"2110065669","repostType":2,"repost":{"id":"2110065669","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612871290,"share":"https://ttm.financial/m/news/2110065669?lang=en_US&edition=fundamental","pubTime":"2021-02-09 19:48","market":"us","language":"en","title":"Israel: vaccinees account for less than 3% of COVID-19 deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2110065669","media":"Reuters","summary":"JERUSALEM, Feb 9 (Reuters) - Fewer than 3% of COVID-19 deaths in Israel over the past month were peo","content":"<html><body><p>JERUSALEM, Feb 9 (Reuters) - Fewer than 3% of COVID-19 deaths in Israel over the past month were peopld who had been vaccinated against the disease, Prime Minister Benjamin Netanyahu said on Tuesday, as his government tries to increase turnout for the Pfizer Inc    shots. </p><p> (Writing by Dan Williams)</p><p>((dan.williams@thomsonreuters.com; +972 (0) 2 6322202; Reuters Messaging: dan.williams.reuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Israel: vaccinees account for less than 3% of COVID-19 deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsrael: vaccinees account for less than 3% of COVID-19 deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-09 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>JERUSALEM, Feb 9 (Reuters) - Fewer than 3% of COVID-19 deaths in Israel over the past month were peopld who had been vaccinated against the disease, Prime Minister Benjamin Netanyahu said on Tuesday, as his government tries to increase turnout for the Pfizer Inc    shots. </p><p> (Writing by Dan Williams)</p><p>((dan.williams@thomsonreuters.com; +972 (0) 2 6322202; Reuters Messaging: dan.williams.reuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2110065669","content_text":"JERUSALEM, Feb 9 (Reuters) - Fewer than 3% of COVID-19 deaths in Israel over the past month were peopld who had been vaccinated against the disease, Prime Minister Benjamin Netanyahu said on Tuesday, as his government tries to increase turnout for the Pfizer Inc    shots.  (Writing by Dan Williams)((dan.williams@thomsonreuters.com; +972 (0) 2 6322202; Reuters Messaging: dan.williams.reuters.com@reuters.net))","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389279425,"gmtCreate":1612782634167,"gmtModify":1704874109955,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"I own all of them...this year is gonna be huge?","listText":"I own all of them...this year is gonna be huge?","text":"I own all of them...this year is gonna be huge?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389279425","repostId":"1163750848","repostType":2,"isVote":1,"tweetType":1,"viewCount":967,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380505507,"gmtCreate":1612545961809,"gmtModify":1704872817656,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Not&nbsp;too&nbsp;good","listText":"Not&nbsp;too&nbsp;good","text":"Not too good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380505507","repostId":"2109722637","repostType":4,"isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380049775,"gmtCreate":1612496806497,"gmtModify":1704871993024,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Tesla ?","listText":"Tesla ?","text":"Tesla ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380049775","repostId":"1125684044","repostType":4,"isVote":1,"tweetType":1,"viewCount":1379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":311590845,"gmtCreate":1611808529287,"gmtModify":1704863755808,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OBSV\">$Obseva Sa(OBSV)$</a>Be patient ?","listText":"<a href=\"https://laohu8.com/S/OBSV\">$Obseva Sa(OBSV)$</a>Be patient ?","text":"$Obseva Sa(OBSV)$Be patient ?","images":[{"img":"https://static.tigerbbs.com/71cc7a9e69f3b571eb6ba4d2a14ba4cc","width":"1242","height":"2385"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/311590845","isVote":1,"tweetType":1,"viewCount":1008,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885276880,"gmtCreate":1631800609540,"gmtModify":1676530639483,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Everyday goes down&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Everyday goes down&nbsp;","text":"$Tiger Brokers(TIGR)$Everyday goes down","images":[{"img":"https://static.tigerbbs.com/13b660a5446aa4be321d11fa689957a8","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885276880","isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885978034,"gmtCreate":1631753960928,"gmtModify":1676530625545,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Cut losses and move on.&nbsp;Not worried&nbsp;anymore.","listText":"<a href=\"https://laohu8.com/S/SURF\">$Surface Oncology(SURF)$</a>Cut losses and move on.&nbsp;Not worried&nbsp;anymore.","text":"$Surface Oncology(SURF)$Cut losses and move on. Not worried anymore.","images":[{"img":"https://static.tigerbbs.com/e2d7af4f061899ec6557834e13245ff5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/885978034","isVote":1,"tweetType":1,"viewCount":3632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":340124773,"gmtCreate":1617360530392,"gmtModify":1704699169785,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/340124773","repostId":"1112964874","repostType":4,"isVote":1,"tweetType":1,"viewCount":3757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386797164,"gmtCreate":1613271151458,"gmtModify":1704879660334,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/386797164","repostId":"2111722630","repostType":2,"repost":{"id":"2111722630","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613214929,"share":"https://ttm.financial/m/news/2111722630?lang=en_US&edition=fundamental","pubTime":"2021-02-13 19:15","market":"us","language":"en","title":"Vivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end","url":"https://stock-news.laohu8.com/highlight/detail?id=2111722630","media":"Reuters","summary":"By Dominique Vidalon   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribut","content":"<html><body><p>By Dominique Vidalon</p><p>   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year. </p><p>   The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.  </p><p>   \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group <a href=\"https://laohu8.com/S/UMG.AU\">$(UMG.AU)$</a> to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.</p><p>   The French conglomerate said the distribution would take the form of a special dividend.</p><p>    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.</p><p>   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.  </p><p>   Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.</p><p>   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    </p><p>($1 = 0.8252 euros)</p><p> (Reporting by Dominique Vidalon. Editing by Jane Merriman)</p><p>((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivendi plans to distribute 60% of UMG capital to shareholders, list it by year-end\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-13 19:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Dominique Vidalon</p><p>   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year. </p><p>   The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.  </p><p>   \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group <a href=\"https://laohu8.com/S/UMG.AU\">$(UMG.AU)$</a> to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.</p><p>   The French conglomerate said the distribution would take the form of a special dividend.</p><p>    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.</p><p>   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.  </p><p>   Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.</p><p>   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    </p><p>($1 = 0.8252 euros)</p><p> (Reporting by Dominique Vidalon. Editing by Jane Merriman)</p><p>((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","TCEHY":"腾讯控股ADR","00700":"腾讯控股","TME":"腾讯音乐"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111722630","content_text":"By Dominique Vidalon   PARIS, Feb 13 (Reuters) - Vivendi    said on Saturday it planned to distribute 60% of Universal Music's capital to investors, subject to shareholder approval, and aimed to list its most-prized asset, home to singers such as Lady Gaga and Taylor Swift, by the end of the year.    The plan to list Universal represents part of a process launched by Vivendi's top shareholder French billionaire Vincent Bollore to cash in on the music industry's revival.     \"Vivendi’s leading institutional shareholders have been pressing for a number of years for a split or the distribution of Universal Music Group $(UMG.AU)$ to reduce Vivendi’s conglomerate discount,\" Vivendi said in a statement.   The French conglomerate said the distribution would take the form of a special dividend.    UMG, a holding company currently being incorporated in the Netherlands, will apply for a listing on Euronext in Amsterdam.   The transaction has received a favorable response from the  consortium led by China's tech group Tencent   , which now controls 20% of UMG, having bought the stake in two successive waves that valued UMG at 30 billion euros ($36.35 billion), Vivendi said.     Vivendi said it would hold an extraordinary shareholders meeting on March 29 to modify the company's by-laws and make the distribution possible.   In addition, Vivendi will propose to distribute a 0.60 euros per share dividend for its 2020 fiscal year at a shareholders meeting scheduled for June 22.    ($1 = 0.8252 euros) (Reporting by Dominique Vidalon. Editing by Jane Merriman)((dominique.vidalon@thomsonreuters.com; +33149495432; Reuters Messaging: dominique.vidalon.reuters.com@reuters.net))","news_type":1,"symbols_score_info":{"QNETCN":0.6,"00700":0.9,"TME":0.9,"TCEHY":0.6}},"isVote":1,"tweetType":1,"viewCount":1040,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":334228981,"gmtCreate":1610812490343,"gmtModify":1704986241717,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/334228981","repostId":"334951881","repostType":1,"repost":{"id":334951881,"gmtCreate":1610640000000,"gmtModify":1716094135529,"author":{"id":"3570684952272154","authorId":"3570684952272154","name":"英伟达官方","avatar":"https://static.tigerbbs.com/a032ec5702e8405d9f658cdcb484031c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570684952272154","idStr":"3570684952272154"},"themes":[],"title":"新年新動力：NVIDIA DRIVE賦能領先電動汽車製造商開啓2021","htmlText":"蔚來汽車、理想汽車和小鵬汽車均採用NVIDIA開發其智能電動車型。 電動汽車造車新勢力已經在行業裏站穩腳跟，並通過採用NVIDIA DRIVE保持發展勢頭。 中國是全球最大的汽車市場，也是電動汽車發展趨勢最明顯的地方，電動汽車初創企業正在迅速普及。蔚來汽車、理想汽車和小鵬汽車正在推動新能源汽車的初步增長，其全新車型通過擴大電池續航里程並增加AI驅動的功能，突破了日常駕駛的極限。 這三家公司2020年的銷量均翻了一倍，總共售出超過十萬三千輛汽車。 這些車型擁有更高效的動力系統，並藉助 NVIDIA DRIVE 爲日常通勤引入全新智能功能。 蔚來推出超算平臺 近期，蔚來宣佈推出搭載NVIDIA DRIVE Orin的超算平臺，驅動其自主和自動駕駛功能。 NIO Adam 超算平臺擁有超1000 TOPS算力的性能，以及安全自動駕駛所需的冗餘和多樣性。它還支持定製化駕駛體驗，學習用戶駕駛習慣和偏好並持續通過車隊數據進行改善。 由NVIDIA DRIVE Orin驅動的超算平臺將在旗艦轎車ET7中首次亮相，預計將於2022年開啓交付，並將應用在未來每款蔚來車型當中。 由NVIDIA DRIVE Orin 驅動的蔚來旗艦轎車ET7 ET7 擁有超過600英里的續航里程和先進的自動駕駛技術，超越了當前車型的功能。作爲首款搭載Adam的汽車，藉助33個傳感器和高性能計算，ET7可以執行城區、高速以及加電等場景點到點自動駕駛體驗。 藉助這種集中式、軟件定義的計算架構，蔚來未來的電動車型將採用最新AI驅動的功能，將其打造爲可永久升級的汽車。 理想汽車驅動向前 去年9月，電動汽車製造商理想汽車表示將採用NVIDIA DRIVE AGX Orin開發其下一代電動汽車。 這些全新車型與一級供應商德賽西威合作開發，具有先進的自動駕駛功能和擴大的電池續航里程以實現真正的智能移動出行。 該高性能平臺將賦","listText":"蔚來汽車、理想汽車和小鵬汽車均採用NVIDIA開發其智能電動車型。 電動汽車造車新勢力已經在行業裏站穩腳跟，並通過採用NVIDIA DRIVE保持發展勢頭。 中國是全球最大的汽車市場，也是電動汽車發展趨勢最明顯的地方，電動汽車初創企業正在迅速普及。蔚來汽車、理想汽車和小鵬汽車正在推動新能源汽車的初步增長，其全新車型通過擴大電池續航里程並增加AI驅動的功能，突破了日常駕駛的極限。 這三家公司2020年的銷量均翻了一倍，總共售出超過十萬三千輛汽車。 這些車型擁有更高效的動力系統，並藉助 NVIDIA DRIVE 爲日常通勤引入全新智能功能。 蔚來推出超算平臺 近期，蔚來宣佈推出搭載NVIDIA DRIVE Orin的超算平臺，驅動其自主和自動駕駛功能。 NIO Adam 超算平臺擁有超1000 TOPS算力的性能，以及安全自動駕駛所需的冗餘和多樣性。它還支持定製化駕駛體驗，學習用戶駕駛習慣和偏好並持續通過車隊數據進行改善。 由NVIDIA DRIVE Orin驅動的超算平臺將在旗艦轎車ET7中首次亮相，預計將於2022年開啓交付，並將應用在未來每款蔚來車型當中。 由NVIDIA DRIVE Orin 驅動的蔚來旗艦轎車ET7 ET7 擁有超過600英里的續航里程和先進的自動駕駛技術，超越了當前車型的功能。作爲首款搭載Adam的汽車，藉助33個傳感器和高性能計算，ET7可以執行城區、高速以及加電等場景點到點自動駕駛體驗。 藉助這種集中式、軟件定義的計算架構，蔚來未來的電動車型將採用最新AI驅動的功能，將其打造爲可永久升級的汽車。 理想汽車驅動向前 去年9月，電動汽車製造商理想汽車表示將採用NVIDIA DRIVE AGX Orin開發其下一代電動汽車。 這些全新車型與一級供應商德賽西威合作開發，具有先進的自動駕駛功能和擴大的電池續航里程以實現真正的智能移動出行。 該高性能平臺將賦","text":"蔚來汽車、理想汽車和小鵬汽車均採用NVIDIA開發其智能電動車型。 電動汽車造車新勢力已經在行業裏站穩腳跟，並通過採用NVIDIA DRIVE保持發展勢頭。 中國是全球最大的汽車市場，也是電動汽車發展趨勢最明顯的地方，電動汽車初創企業正在迅速普及。蔚來汽車、理想汽車和小鵬汽車正在推動新能源汽車的初步增長，其全新車型通過擴大電池續航里程並增加AI驅動的功能，突破了日常駕駛的極限。 這三家公司2020年的銷量均翻了一倍，總共售出超過十萬三千輛汽車。 這些車型擁有更高效的動力系統，並藉助 NVIDIA DRIVE 爲日常通勤引入全新智能功能。 蔚來推出超算平臺 近期，蔚來宣佈推出搭載NVIDIA DRIVE Orin的超算平臺，驅動其自主和自動駕駛功能。 NIO Adam 超算平臺擁有超1000 TOPS算力的性能，以及安全自動駕駛所需的冗餘和多樣性。它還支持定製化駕駛體驗，學習用戶駕駛習慣和偏好並持續通過車隊數據進行改善。 由NVIDIA DRIVE Orin驅動的超算平臺將在旗艦轎車ET7中首次亮相，預計將於2022年開啓交付，並將應用在未來每款蔚來車型當中。 由NVIDIA DRIVE Orin 驅動的蔚來旗艦轎車ET7 ET7 擁有超過600英里的續航里程和先進的自動駕駛技術，超越了當前車型的功能。作爲首款搭載Adam的汽車，藉助33個傳感器和高性能計算，ET7可以執行城區、高速以及加電等場景點到點自動駕駛體驗。 藉助這種集中式、軟件定義的計算架構，蔚來未來的電動車型將採用最新AI驅動的功能，將其打造爲可永久升級的汽車。 理想汽車驅動向前 去年9月，電動汽車製造商理想汽車表示將採用NVIDIA DRIVE AGX Orin開發其下一代電動汽車。 這些全新車型與一級供應商德賽西威合作開發，具有先進的自動駕駛功能和擴大的電池續航里程以實現真正的智能移動出行。 該高性能平臺將賦","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/334951881","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1121,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9907708803,"gmtCreate":1660255727604,"gmtModify":1676531200111,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>Hold","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>Hold","text":"$Tesla Motors(TSLA)$Hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9907708803","isVote":1,"tweetType":1,"viewCount":2382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894786263,"gmtCreate":1628857491852,"gmtModify":1676529876357,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?&nbsp;","listText":"<a href=\"https://laohu8.com/S/VYNE\">$VYNE Therapeutics Inc.(VYNE)$</a>What happen to this company?&nbsp;","text":"$VYNE Therapeutics Inc.(VYNE)$What happen to this company?","images":[{"img":"https://static.tigerbbs.com/a7c206b6845d177c23ae34177ed6d7a5","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894786263","isVote":1,"tweetType":1,"viewCount":2301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386794771,"gmtCreate":1613271099293,"gmtModify":1704879660009,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Sanofi failed his 3rd stages...","listText":"Sanofi failed his 3rd stages...","text":"Sanofi failed his 3rd stages...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386794771","repostId":"2111807728","repostType":2,"repost":{"id":"2111807728","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1613256424,"share":"https://ttm.financial/m/news/2111807728?lang=en_US&edition=fundamental","pubTime":"2021-02-14 06:47","market":"us","language":"en","title":"Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2111807728","media":"Reuters","summary":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Transla","content":"<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi's mRNA COVID-19 vaccine candidate not ready this year-CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-14 06:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>    and U.S. group Translate Bio</p><p>  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.</p><p>   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.</p><p>   In December last year, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.  </p><p>   \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.</p><p>   The CEO gave no other details. Officials at Sanofi were not available for comment.</p><p>   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .</p><p>   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.  </p><p>   To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.  </p><p>   Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.</p><p>   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.</p><p> (Reporting by Matthias Blamont; Editing by Dominique Vidalon)</p><p>((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","TBIO":"Telesis Bio, Inc.","PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111807728","content_text":"PARIS, Feb 13 (Reuters) - A COVID-19 vaccine candidate developed by Sanofi    and U.S. group Translate Bio  \"will not be ready this year,\" the French drugmaker's chief executive told Le Journal du Dimanche newspaper.   Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer   /BioNTech    and Moderna    --, are expected to start this quarter.   In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data.     \"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue,\" Paul Hudson was quoted as saying.   The CEO gave no other details. Officials at Sanofi were not available for comment.   The news could mark another blow for Sanofi, already embattled with a delay for another COVID-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline   .   The two groups stunned investors last year by warning their traditional, protein-based COVID-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.     To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.     Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.   Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly. (Reporting by Matthias Blamont; Editing by Dominique Vidalon)((matthias.blamont@thomsonreuters.com; +33 1 4949 5054 ; @matthiasblamont))","news_type":1,"symbols_score_info":{"PFE":0.9,"TBIO":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380505507,"gmtCreate":1612545961809,"gmtModify":1704872817656,"author":{"id":"3553468686052330","authorId":"3553468686052330","name":"ChunPeng","avatar":"https://static.tigerbbs.com/f64d90920e0ea1b28e2b3c3a97f2a493","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3553468686052330","idStr":"3553468686052330"},"themes":[],"htmlText":"Not&nbsp;too&nbsp;good","listText":"Not&nbsp;too&nbsp;good","text":"Not too good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380505507","repostId":"2109722637","repostType":4,"isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}